In this deep dive, BioSpace explores the diverse therapeutic modalities now in development, as well as the opportunities and battles for market dominance in this emerging space.

circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 400 patents and patent applications ...

The discovery could pave the way for a groundbreaking RNA-based multi-cancer treatment. Alternative RNA splicing functions ...

A study reveals how cancer disrupts RNA splicing and presents a potential therapy using antisense oligonucleotides to target ...

Researchers have discovered that cancer cells suppress 'poison exons' -- genetic elements that act as an off switch for protein production -- in a key gene called TRA2 , promoting tumor growth. By ...

LCGC International spoke with Daniel Meston and Dwight Stoll from Gustavus Adolphus College in St. Peter, Minnesota, USA, ...

Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), ”), a leader in RNA-based therapeutics, announced today the successful completion of a Phase 1 clinical trial ...

Scientists reveal how cancer cells manipulate RNA splicing, increasing tumor growth. A new study introduces antisense ...

Scientists from The Jackson Laboratory and UConn Health found that cancer cells disrupt poison exons, leading to tumor growth ...

ELRIG meeting on Therapeutic Oligonucleotides brings together esteemed scientists from academia, industry, and other members ...

MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp (a) inhibitor from China's Jiangsu Hengrui ...